Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

41. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials

Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular (...) baseline characteristics such as percutaneous transluminal coronary angioplasty (range 18.4 to 93%); stroke (3.4 to 10.8%); peripheral vascular disease (7.1 to 42.3%); diabetes (11.8% to 38.9%); the use of concomitant medications such as lipid lowering drugs (0.1 to 70%); and in open label angiotensin-converting enzyme inhibitor use in placebo groups (8.1 to 23%). Two authors independently conducted the searches. It was not clear if the statement 'differences were resolved by discussion' applied

DARE.2007

42. Major congenital malformations after first-trimester exposure to ACE inhibitors.

Major congenital malformations after first-trimester exposure to ACE inhibitors. BACKGROUND: Use of angiotensin-converting-enzyme (ACE) inhibitors during the second and third trimesters of pregnancy is contraindicated because of their association with an increased risk of fetopathy. In contrast, first-trimester use of ACE inhibitors has not been linked to adverse fetal outcomes. We conducted a study to assess the association between exposure to ACE inhibitors during the first trimester (...) of pregnancy only and the risk of congenital malformations. METHODS: We studied a cohort of 29,507 infants enrolled in Tennessee Medicaid and born between 1985 and 2000 for whom there was no evidence of maternal diabetes. We identified 209 infants with exposure to ACE inhibitors in the first trimester alone, 202 infants with exposure to other antihypertensive medications in the first trimester alone, and 29,096 infants with no exposure to antihypertensive drugs at any time during gestation. Major

NEJM2006

43. Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy

Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy Article Text Therapeutics Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy Free Edgar

Evidence-Based Medicine (Requires free registration)2006

44. Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI

Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI Article Text Therapeutics Review: angiotension receptor blockers do not differ from ACE inhibitors in chronic heart failure or acute MI Free Thomas H Lee , MD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

45. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data MacKinnon M (...) , Shurraw S, Akbari A, Knoll G A, Jaffey J, Clark H D CRD summary The authors concluded that the combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker was associated with a short-term decrease in proteinuria in adults with chronic proteinuric renal disease, and appeared safe. Overall, this was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To determine the efficacy of combination therapy with an angiotensin

DARE.2006

46. Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain

Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain Article Text Therapeutics Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

47. Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy

Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy Article Text Therapeutics Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic

Evidence-Based Medicine (Requires free registration)2006

48. Concomitant loop diuretics and ACE inhibitors increase risk of lithium toxicity in elderly people

Concomitant loop diuretics and ACE inhibitors increase risk of lithium toxicity in elderly people Concomitant loop diuretics and ACE inhibitors increase risk of lithium toxicity in elderly people | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Concomitant loop diuretics and ACE inhibitors increase risk of lithium toxicity in elderly people Article Text Aetiology Concomitant loop diuretics and ACE inhibitors increase risk of lithium toxicity in elderly people Free Robin Jacoby , DM, FRCP Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2005

49. Prognostic benefit of beta-blockers in patients not receiving ACE-inhibitors

Prognostic benefit of beta-blockers in patients not receiving ACE-inhibitors Prognostic benefit of beta-blockers in patients not receiving ACE-inhibitors Prognostic benefit of beta-blockers in patients not receiving ACE-inhibitors Krum H, Haas S J, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J CRD summary This poorly reported review aimed to assess the effect of beta-blockers (BBs) on mortality and hospitalisation rates in patients with chronic (...) heart failure, not treated with angiotensin-converting enzyme inhibitors (ACE-I). The authors concluded that BBs and ACE-I have similar benefits, despite the absence of comparative studies. The findings are unlikely to be reliable given the limitations of the review methods. Authors' objectives The authors' stated objective was to determine the effect of beta-blockers (BBs) on mortality and heart failure (HF) hospitalisation rate in patients with systolic chronic HF who were not treated

DARE.2005

50. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis

Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis Smith D G, Cerulli A, Frech F H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the addition of valsartan to usual care for the treatment of heart failure (HF) in patients not taking angiotensin-converting enzyme (ACE) inhibitors because of side effects or contraindications. Valsartan was given at a starting dose of 40 mg twice daily and titrated to a target

NHS Economic Evaluation Database.2005

51. ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension

ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension Article Text Therapeutics ACE inhibitors reduced cardiovascular events and all cause mortality in elderly people with hypertension Free Richard Davidson , MD, MPH Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2004

52. Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non-diabetic renal disease

Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non-diabetic renal disease Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non-diabetic renal disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non-diabetic renal disease Article Text Therapeutics Combination ACE inhibitor and angiotensin receptor blocker therapy was better than monotherapy in non

Evidence-Based Medicine (Requires free registration)2004

53. Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus

Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Cost effectiveness of ACE inhibitor treatment for patients with Type 1 diabetes mellitus Dong F B, Sorensen S W, Manninen D L, Thompson T J, Narayan V, Orians C E, Gregg E W, Eastman R C, Dasbach E J, Herman W H, Newman J M, Narva A S, Ballard D J, Engelgau M M Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The initiation of treatment with an angiotensin-converting enzyme (ACE) inhibitor (captopril) was assessed in adult patients with Type I diabetes. Treatment immediately after diagnosis was compared with treatment after the onset

NHS Economic Evaluation Database.2004

54. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan (...) treatment in patients with Type 2 diabetes, hypertension, and renal disease Cost-effectiveness of early irbesartan treatment versus control (standard antihypertension medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with Type 2 diabetes, hypertension, and renal disease Palmer A J, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby R A, De Zeeuw D, Parving H H

NHS Economic Evaluation Database.2004

55. ACE inhibitors update

ACE inhibitors update ACE inhibitors update ACE inhibitors update Oertel M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Oertel M. ACE inhibitors update. University HealthSystem Consortium (UHC). Drug Monograph. 2004 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals (...) comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Angiotensin-Converting Enzyme Inhibitors Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu AccessionNumber 32006001047 Date bibliographic record

Health Technology Assessment (HTA) Database.2004

56. Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency

Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency Meta-analysis: effect of ACE-inhibitors on outcomes in patients with renal insufficiency Terajima T, Yamagata S, Satoh N, Ueda S CRD summary This review assessed the efficacy of angiotensin-converting enzyme (ACE) inhibitors in slowing the progression to end-stage renal failure in patients with renal disease (...) . The authors concluded that ACE inhibitors are effective in slowing the progression of renal insufficiency regardless of baseline serum creatinine levels. Poor reporting of the review process makes it difficult to verify this conclusion. Authors' objectives To determine the effect of angiotensin-converting enzyme (ACE) inhibitors in slowing progression to end stage renal failure (ESRF) in patients with renal disease. Searching MEDLINE (from 1966 to 2001) and Igaku-Chuo-Zasshi (from 1987 to 2002) were

DARE.2003

57. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors.

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Angio-oedema is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Angio-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P (...) and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and in 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0 003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.

Lancet2002

58. beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.

beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Blood concentrations of angiotensin II are often raised in patients with heart failure, despite treatment with angiotensin-converting-enzyme (ACE) inhibitors. We compared concentrations of angiotensin II in two groups of matched patients, receiving ACE inhibitor therapy with or without concomitant administration of beta-blockers. Concentrations of angiotensin II were lower in individuals taking beta-blockers than (...) in those who were not (geometric mean 1.1 [95% CI 0.4-2.7] vs 15.5 [4.6-52.6] fmol/mL, 95% CI for difference 3-59). Our findings indicate that a reduction in angiotensin II concentrations might contribute to the therapeutic benefits of beta-blockade in heart failure, especially in patients who simultaneously receive ACE inhibitor treatment.

Lancet2001

59. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial.

Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. 11343737 2001 05 09 2001 06 07 2015 06 16 0140-6736 357 9265 2001 Apr 28 Lancet (London, England) Lancet Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. 1321-4 The DD genotype for the angiotensin-I converting enzyme (ACE I) deletion allele (D) polymorphism (...) is a possible genetic risk factor for restenosis after coronary stent implantation. We aimed to establish whether or not blockade of ACE with high doses of ACE inhibitors could reduce this risk of angiographic restenosis. We characterised the ACE I/D polymorphism in 345 consecutive patients who were undergoing coronary stenting. 115 had the DD genotype. We assigned 91 of these 115 patients to quinapril 40 mg daily (n=46) or placebo (n=45). Treatment was started within 48 h after stent implantation

Lancet2001

60. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes Pahor M, Psaty B M, Alderman M H, Applegate W B, Williamson J D, Furberg C D Authors' objectives To assess whether angiotensin-converting enzyme (ACE) inhibitors and other hypertensive (...) drugs are superior to alternative agents for the prevention of cardiovascular events in patients with hypertension and type 2 diabetes. Searching PubMed was searched to January 2000 using the following keywords: 'ACE inhibitors', 'diabetes', 'hypertension', and 'clinical trial'. The authors also checked the bibliographies of retrieved articles for additional studies, and contacted their colleagues for information on more recently published articles. Study selection Study designs of evaluations

DARE.2000